OncoMatch/Clinical Trials/NCT06458712
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Is NCT06458712 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies DSB2455 for advanced cancers (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain mets) with specific mutations (homologous recombination deficiency).
Treatment: DSB2455 — Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Prostate Cancer
Ovarian Cancer
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cancer treatment
Has received prior cancer treatment as outlined in the protocol
Cannot have received: PARP1-selective inhibitor
Has received a prior PARP1-selective inhibitor
Cannot have received: radiation therapy to the lung >30Gy
Has received radiation therapy to the lung that is >30Gy within 6 months of the first dose of study intervention
Lab requirements
Blood counts
Adequate organ function as defined in the protocol
Kidney function
Adequate organ function as defined in the protocol
Liver function
Adequate organ function as defined in the protocol
Cardiac function
Impaired cardiac function or clinically significant cardiac disease [excluded]
Adequate organ function as defined in the protocol. Impaired cardiac function or clinically significant cardiac disease [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale Cancer Center - Yale New Haven Hospital · New Haven, Connecticut
- Tisch Cancer Institute Icahn School of Medicine at Mount Sinai · New York, New York
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06458712 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP1-selective inhibitor, radiation therapy to the lung >30Gy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages